USPTO serial 76113582
EPIGENESIS PHARMACEUTICALS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- MICHOS, JOHN E
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with EPIGENESIS PHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
EPIGENESIS PHARMACEUTICALS, INC.
CRANBURY, NJ
EPIGENESIS Pharmaceuticals, Inc.
Cranbury, NJ
EPIGENESIS Pharmaceuticals, Inc.
Cranbury, NJ
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Dr. Viviana Amzel
ALBERT P HALLUIN WILSON SONSINI GOODRICH & ROSATI650 PAGE MILL RDPALO ALTO, CA 94304-1050UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ARDS), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (SVT), adenosine stress tests, infantile respiratory distress syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostate | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by EPIGENESIS PHARMACEUTICALS, INC.
- Other trademarks owned by EPIGENESIS Pharmaceuticals, Inc.
- Other trademarks owned by EPIGENESIS Pharmaceuticals, Inc.
- Other trademarks in Class 005
- Similar marks named EPIGENESIS PHARMACEUTICALS
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 21, 2006 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 21, 2006 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 1, 2005 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jul 1, 2005 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jul 1, 2005 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 10, 2005 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Dec 23, 2004 | EXT4 | SOU EXTENSION 4 FILED | — |
| Dec 23, 2004 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 30, 2004 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jul 19, 2004 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 16, 2004 | PAPER RECEIVED | — | |
| Jul 13, 2004 | CFIT | CASE FILE IN TICRS | — |
| Jul 6, 2004 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jul 6, 2004 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 7, 2004 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jan 7, 2004 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jan 7, 2004 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 17, 2003 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 9, 2003 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 8, 2003 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 14, 2003 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 22, 2002 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 2, 2002 | NPUB | NOTICE OF PUBLICATION | — |
| Jul 24, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 30, 2002 | 1.AD | SEC. 1(A) CLAIM DELETED | — |
| May 30, 2002 | 1.BA | Sec. 1(B) CLAIM ADDED | — |
| May 30, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 11, 2002 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 31, 2001 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 21, 2001 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |